MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-27-2026
Hoth Therapeutics Market Cap 2011-2026 | HOTH
As of April 17, 2026 Hoth Therapeutics has a market cap of $ 10.2 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Hoth Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.2 M | 6.57 M | 5.18 M | 2.45 M | 506 K | 26.1 M | 43.1 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 43.1 M | 506 K | 13.6 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.97 | 6.43 % | $ 9.55 B |  Australia |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M |  USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | France |
 |
Akari Therapeutics, Plc
AKTX
|
8.08 B | $ 5.12 | 11.55 % | $ 345 B |  Britain |
 |
Aligos Therapeutics
ALGS
|
65.9 M | $ 7.66 | 3.23 % | $ 75.7 M | USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
40.8 B | $ 320.13 | -3.98 % | $ 41.9 B | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 21.81 | 0.6 % | $ 1.02 B | USA |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 4.67 | -1.37 % | $ 766 M | Britain |
 |
Applied Therapeutics
APLT
|
541 M | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 102.12 | 2.66 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 3.08 | -4.94 % | $ 5.07 M |  Israel |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
334 M | $ 1.35 | -12.9 % | $ 347 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
467 M | $ 4.26 | 0.47 % | $ 456 M | USA |
 |
AstraZeneca PLC
AZN
|
81.2 B | - | - | $ 96.9 B | Britain |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 24.19 | -1.59 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
6.33 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.61 | 8.05 % | $ 428 M | Britain |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
67 M | - | - | $ 546 M | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Cidara Therapeutics
CDTX
|
148 M | - | - | $ 1.41 B | USA |
 |
BioXcel Therapeutics
BTAI
|
15.4 M | $ 1.07 | 1.9 % | $ 13.1 M | USA |
 |
Cabaletta Bio
CABA
|
283 M | $ 3.52 | 3.53 % | $ 354 M | USA |
 |
CymaBay Therapeutics
CBAY
|
3.43 B | - | - | $ 3.45 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
ChromaDex Corporation
CDXC
|
431 M | - | -0.88 % | $ 598 M | USA |